Antiphospholipid Antibodies and Retinal Thrombosis in Patients Without Risk Factors

Cobo-Soriano, Rosario; Sánchez‐Ramón, Silvia; Aparicio, M

doi:10.1097/00132578-200004000-00016

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antiphospholipid antibodies are associated with arterial and venous occlusion, and several studies have linked them to RVO, often in those with relatively younger age. [41][42][43] Other studies, however, have not confirmed this association. A recent casecontrolled study found no association between RVO patients and thrombophilic risk factors including antiphospholipid antibodies and homocysteine.…”

Section: Risk Factorsmentioning

confidence: 89%

“…Associations with factor V Leiden, hyperhomocysteinemia, protein C and S deficiency, antiphospholipid antibody syndrome and factor XII deficiency have all been reported with CRVO. [34][35][36][37][38][39][40][41][42][43][44][45][46] Most of these studies, however, are retrospective, have included all forms of RVO, have small sample sizes and have, for many of the factors investigated, shown conflicting results.…”

Section: Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Central retinal vein occlusion: a review

McAllister

2011

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Central retinal vein occlusion remains a common cause of unilateral visual loss. Until recently, our treatment options for this condition were limited only to laser photocoagulation for the devastating end sequelae of anterior segment neovascularization. Over the last 2 years, a number of randomized controlled trials have given us significant new treatment options to address not only visual loss from macular oedema but also the ability to create a bypass around the obstruction in the central retinal vein and to address the raised venous hydrostatic pressure. In the future, it is likely that combination approaches to the management of central retinal vein occlusion will develop using specific agents and techniques to address the components of macular oedema, retinal ischaemia and raised venous hydrostatic pressure, all of which combine to produce the clinical picture and the reduction in vision seen in this condition.

show abstract

Section: Risk Factorsmentioning

confidence: 89%

Section: Risk Factorsmentioning

confidence: 99%

Central retinal vein occlusion: a review

McAllister

2011

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

“…To prospectively assess the prevalence of antiphospholipid antibodies (aPL) in patients who were investigated for their retinal vascular occlusion, the following was reported [12]: the prevalence of anticardiolipin antibodies (aCL) in the study group was 22.5% (Table 1) compared to 5% in a group of apparently healthy individuals. However, the antibody assay for lupus anticoagulant was negative in all patients.…”

Section: The Prevalence Of Eye Involvement In Apsmentioning

confidence: 99%

“…The development of rubeosis in these patients could be predicted by fluorescein angiography in 82% and by ERG [12][13][14] in 94% of patients. Fluorescein angiography misjudged nine (28%) patients, whereas ERG only misjudged one patient.…”

Section: Diagnostic Procedures For Defining Retinopathy?mentioning

confidence: 99%

Looking Into the Eyes of Patients with Antiphospholipid Syndrome

Yehudai

Shoenfeld

Toubi

2007

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Diagnosis of antiphospholipid syndrome (APS) should be considered in all patients with recurrent systemic or ocular thrombosis in the absence of known risk factors. Because of the frequent ocular involvement in APS patients (as many as 80%), an ophthalmologic assessment should become a routine part of the clinical work-up of all patients in whom APS is highly suspected. The presence of isolated ocular thrombosis with persistently increased titers of antiphospholipid antibodies should be considered as definite APS. Ocular involvement in APS is frequently associated with other manifestations of the central nervous system (CNS), such as transient ischemic attack or cerebral vascular events. Diagnostic tools are needed to better establish a diagnosis of retinal vascular thrombosis. The treatment of isolated ocular APS should be based on the same principles as in all patients with systemic APS. Anticoagulation is aimed to prevent recurrent ocular or cerebral thromboses.

show abstract

Retinal vein occlusions in patients taking warfarin*1

Browning

Fraser

2004

Ophthalmology

View full text Add to dashboard Cite

Antiphospholipid Antibodies and Retinal Thrombosis in Patients Without Risk Factors

Cited by 3 publications

References 0 publications

Central retinal vein occlusion: a review

Central retinal vein occlusion: a review

Looking Into the Eyes of Patients with Antiphospholipid Syndrome

Retinal vein occlusions in patients taking warfarin*1

Contact Info

Product

Resources

About